ABO blood marker carbohydrates - D-galactose, L-fucose, N-acetylgalactosamine, and N-acetylglucosamine
Unknown authorUnknown author (Openverse / BY-SA 4.0) / Openverse BY-SA 4.0
Peptide Therapies/November 8, 2026/2 min read

Blood Markers May Help Predict Who Benefits Most From Teplizumab

A new study identifies metabolic signatures in the blood that could help doctors predict whether someone with newly diagnosed Type 1 diabetes will respond well to teplizumab treatment.

Research summaryPubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

peptidesGLP-1C-peptideimmunotherapyadjunct therapy

Key takeaways

  • Researchers found 15 metabolites (substances in the blood) that differ between people who respond well to teplizumab and those who don't.
  • Responders to teplizumab had higher levels of certain metabolites related to energy production and gut bacteria, while non-responders had elevated levels of others like glutamate.
  • A machine learning model using these metabolites predicted treatment response with about 77% accuracy in testing.
  • This type of predictive tool could eventually help identify which newly diagnosed patients might benefit most from teplizumab before starting treatment.
  • The findings need further validation in larger groups before they can be used clinically.

What This Study Looked At

Researchers from the AbATE trial examined blood samples from 41 people who had just been diagnosed with Type 1 diabetes. They wanted to understand why some people respond better to teplizumab than others. Using advanced laboratory techniques, they measured hundreds of metabolites—small molecules produced during normal metabolism—in blood samples taken before treatment started.

They defined treatment response based on how well the pancreas preserved its ability to produce insulin. People whose insulin-producing ability declined by less than 45% over two years were considered responders; those with greater declines were non-responders.

The Metabolic Differences Between Responders and Non-Responders

The researchers found significant differences in 15 metabolites between the two groups. Responders had higher levels of metabolites involved in the body's energy production (TCA cycle intermediates), certain amino acid derivatives, and compounds derived from gut bacteria. Non-responders, by contrast, showed elevated levels of glutamate and acylcarnitines.

These differences suggest that baseline metabolic patterns may reflect underlying biological differences that influence how someone's immune system responds to teplizumab treatment.

Can These Markers Predict Response?

The researchers used these 15 metabolites to build a predictive computer model. When tested on new data, the model correctly identified who would respond to teplizumab about 77% of the time. The model performed well when evaluated using multiple rigorous testing approaches, including cross-validation and permutation testing.

While these results are encouraging, they come from a small sample of 41 people. The researchers emphasize that further validation in larger groups is necessary before this type of metabolic profiling could be used in clinical practice to guide treatment decisions.

What Could This Mean for Patients?

If validated, a blood test identifying these metabolic signatures could eventually help doctors identify which newly diagnosed Type 1 diabetes patients are more likely to benefit from teplizumab. This could help inform treatment decisions before starting therapy. The researchers also suggest that similar approaches might work for other immunotherapies being developed to prevent or delay Type 1 diabetes.

However, this is still research-stage work. Much more testing is needed before any metabolomic test becomes available in clinical practice.

Evidence label

Source: Diabetes. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

From Type1Cure

Read more of our own writing in Stories

More evidence-labeled coverage across the Type1Cure library.